Royal Bank of Canada
SGP

Royal Bank of Canada’s SpyGlass Pharma SGP Stock Holding History

Royal Bank of Canada’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Buy
589
+504
+593% +$10.9K ﹤0.01% 6565
2026
Q1 		$2K Buy
+85
New +$2.29K ﹤0.01% 6801

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Royal Bank of Canada's SGP Position: Q2 2026 in Review

Royal Bank of Canada increased its SpyGlass Pharma (SGP) stake by 593% in Q2 2026, buying an estimated $10.9K and bringing the position to 589 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #6565.

Royal Bank of Canada first reported a position in SGP in Q1 2026 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold SGP as of Q2 2026.

  • Royal Bank of Canada held 589 shares of SpyGlass Pharma worth $13K as of Q2 2026.
  • Royal Bank of Canada bought 504 SpyGlass Pharma shares in Q2 2026, an estimated $10.9K.
  • SpyGlass Pharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6565 holding.
  • Royal Bank of Canada first reported a position in SpyGlass Pharma in Q1 2026 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.